Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal research hub

A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)

This study looks at a new medicine called Romiplostim for people with certain cancers who are having chemotherapy. It aims to see if Romiplostim can help prevent low platelet counts, which are tiny blood cells important for stopping bleeding, caused by chemotherapy.